In the run-up to this weekend's G-8 summit at Camp David, journalists have unfavorably compared European "austerity" with Barack Obama's economic policies.

Congress is getting in the holiday spirit, and top on their gift list for American workers is extending President Obama’s payroll tax holiday, set to expire at the end of the year. But, as is the case with many gift ideas, this one sounds better than it is in real life.

Europe’s proposed financial firewall around Spain and Italy will prove any more effective in protecting those countries from another market onslaught than was the Maginot line in protecting France. The very design of the proposed firewall appears to be basically flawed in dealing with a renewed loss of market confidence in the euro’s long-run sustainability.

Many commentators argue that uncertainty about taxes, government spending and other policy matters deepened the recession of 2007-2009 and slowed the recovery. To investigate this issue we develop a new index of policy-related economic uncertainty and estimate its dynamic relationship to output, investment and employment.

Inspired by President Obama’s cheap election-year politicking, Congress has launched into a frenzied, bipartisan panderfest over the Stafford loan program. Late last week, an emotional House speaker John Boehner led House Republicans to vote for an Obama-proposed giveaway he’d denounced just a few days previously.For those who don’t...

Taxmageddon is the result of the extreme shortsightedness of President Obama and the Democrats, who extended current tax policies for only two years back in 2010. The latest research suggests that the economy will suffer severely this year for that shortsightedness.

Obama claims that letting most of the Bush tax cuts expire will bring tax rates back to what they were under Clinton, but fails to recognize that the current administration and that under Clinton are far from analogous.

Biologics are essential to oncology care. As patents for older biologics begin to expire, the United States is developing an abbreviated regulatory process for the approval of similar biologics, which raises important considerations for the safe and appropriate incorporation of biosimilars into clinical practice for patients with cancer.